Author

Diane Heiser

Prelude Therapeutics Incorporated (United States)ORCID 0009-0008-1757-914XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto J. ArribasiD· 1 shared Anastasios StathisiD· 1 shared Andrea RinaldiiD· 1 shared Davide RossiiD· 1 shared Eleonora CannasiD· 1 shared Francesca GuidettiiD· 1 shared Francesco BertoniiD· 1 shared Luciano CascioneiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors

Eleonora Cannas, Alberto J. Arribas, Luciano Cascione, Francesca Guidetti, Andrea Rinaldi, Davide Rossi, Anastasios Stathis, Diane Heiser, Francesco Bertoni

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

bioRxiv · Feb 11, 2026 · PreprintCancer Biology